TECH Stock Analysis: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$72.09
0.06 (0.08%)
▲
5d:
+0.68%
30d:
+1.54%
90d:
+30.31%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TECH shows positive signals but monitor for confirmation. Market pricing in 8.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TECH shows positive signals but monitor for confirmation. Market pricing in 8.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.97
Based on 5.3% avg growth
INTRINSIC VALUE TODAY
$40.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $72.09, which is considered fair relative to its 30-day fair value range of $65.44 to $74.35. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.3) compared to its historical average (27.9). At these levels, the market is pricing in 8.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $71.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TECH is in a strong uptrend. The price is currently testing key support at $71.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$65.44 -
$74.35
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($69.73)
- NEUTRAL: PE elevated vs history but 8.2% growth expectation is conservative given 129% recent growth
Trading Range Analysis
30-Day Trading Range
$65.44 -
$74.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$71.45
Resistance Level
$72.37
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.28
Wall Street Target
$69.73
(-3.3%)
Revenue Growth (YoY)
-1.5%
Earnings Growth (YoY)
128.6%
Profit Margin
9.0%
Valuation Premium vs History
+8.2% premium
PE vs Historical
35.3 vs 27.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.2%
(market-implied from PE analysis)
1-Year Target
$78.00
(+8%)
2-Year Target
$84.40
(+17%)
3-Year Target
$91.32
(+27%)
3-Yr Target (if PE normalizes)
(PE: 35→28)
PE COMPRESSION
$72.22
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.3, Growth: 6.5%)
$87.12
(+21%)
Base:
(SPY PE: 20.7, Growth: 6.5%)
$51.19
(-29%)
Bear:
(PE: 17.6, Growth: 6.5%)
$43.51
(-40%)
📈
Valuation based on Current Earnings
Forward PE: 34.36 | Forward EPS (Implied): $2.10
Bull Case
$87.05
(+21%)
Analyst growth 15.0%, PE expands to 36.1
Base Case
$72.09
(0%)
Market implied 0.0%, PE stable at 34.4
Bear Case
$55.15
(-24%)
Severe decline -15.0%, PE contracts to 30.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 02, 2026 11:19 PM ET
Data refreshes hourly during market hours. Next update: 12:19 AM
Data refreshes hourly during market hours. Next update: 12:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
BUY
2026-03-30
April McClain Delaney
SELL
2026-03-26
April McClain Delaney
SELL
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$108 | 60 BUY |
